Testosterone therapy reduces hepatic steatosis in men with type 2 diabetes and low serum testosterone concentrations

Abstract

Testosterone therapy was associated with a reduction in hepatic steatosis in men with diabetes and low serum testosterone. Future randomised studies of testosterone therapy in men with NAFLD focusing on liver-related endpoints are therefore justified.